Abstract
Despite enormous effort, promising pre-clinical data in animal studies and over 900 clinical trials in the United States, no cancer vaccine has ever been approved for clinical use. Over the past decade a great deal of progress has been in both laboratory and clinical studies defining the interactions between developing tumors and the immune system. The results of these studies provide a rationale that may help explain the failure of recent therapeutic cancer vaccines in terms of vaccine principles, in selecting which tumors are the most appropriate to target and instruct the design and implementation of state-of-the-art cancer vaccines.
| Original language | English |
|---|---|
| Pages (from-to) | 105-112 |
| Number of pages | 8 |
| Journal | Seminars in Immunology |
| Volume | 22 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jun 1 2010 |
Fingerprint
Keywords
- Cancer
- Immunosurveillance
- Immunotherapy
- Vaccine(s)
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
Tumor immunogenicity and responsiveness to cancer vaccine therapy : The state of the art. / Schreiber, Taylor H.; Raez, Luis; Rosenblatt, Joseph D; Podack, Eckhard R.
In: Seminars in Immunology, Vol. 22, No. 3, 01.06.2010, p. 105-112.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tumor immunogenicity and responsiveness to cancer vaccine therapy
T2 - The state of the art
AU - Schreiber, Taylor H.
AU - Raez, Luis
AU - Rosenblatt, Joseph D
AU - Podack, Eckhard R.
PY - 2010/6/1
Y1 - 2010/6/1
N2 - Despite enormous effort, promising pre-clinical data in animal studies and over 900 clinical trials in the United States, no cancer vaccine has ever been approved for clinical use. Over the past decade a great deal of progress has been in both laboratory and clinical studies defining the interactions between developing tumors and the immune system. The results of these studies provide a rationale that may help explain the failure of recent therapeutic cancer vaccines in terms of vaccine principles, in selecting which tumors are the most appropriate to target and instruct the design and implementation of state-of-the-art cancer vaccines.
AB - Despite enormous effort, promising pre-clinical data in animal studies and over 900 clinical trials in the United States, no cancer vaccine has ever been approved for clinical use. Over the past decade a great deal of progress has been in both laboratory and clinical studies defining the interactions between developing tumors and the immune system. The results of these studies provide a rationale that may help explain the failure of recent therapeutic cancer vaccines in terms of vaccine principles, in selecting which tumors are the most appropriate to target and instruct the design and implementation of state-of-the-art cancer vaccines.
KW - Cancer
KW - Immunosurveillance
KW - Immunotherapy
KW - Vaccine(s)
UR - http://www.scopus.com/inward/record.url?scp=77953610923&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953610923&partnerID=8YFLogxK
U2 - 10.1016/j.smim.2010.02.001
DO - 10.1016/j.smim.2010.02.001
M3 - Article
C2 - 20226686
AN - SCOPUS:77953610923
VL - 22
SP - 105
EP - 112
JO - Seminars in Immunology
JF - Seminars in Immunology
SN - 1044-5323
IS - 3
ER -